Senti Biosciences Inc
SNTI1.200USD
+0.030+2.56%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
31.55MMarket Cap
LossP/E TTM
More Details of Senti Biosciences Inc Company
Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.
Senti Biosciences Inc Info
Ticker SymbolSNTI
Company nameSenti Biosciences Inc
IPO dateMay 26, 2021
CEOLu (Timothy)
Number of employees34
Security typeOrdinary Share
Fiscal year-endMay 26
Address2 Corporate Drive, First Floor
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16502392030
Websitehttps://www.sentibio.com/
Ticker SymbolSNTI
IPO dateMay 26, 2021
CEOLu (Timothy)
Company Executives of Senti Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
33.00K
--
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Independent Director
17.61K
--
Mr. Bryan Baum
Mr. Bryan Baum
Director
Director
--
--
Ms. Frances D. Schulz
Ms. Frances D. Schulz
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Donald Tang
Mr. Donald Tang
Director
Director
--
--
Mr. Jay Cross
Mr. Jay Cross
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. Feng Hsiung
Mr. Feng Hsiung
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
33.00K
--
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Independent Director
17.61K
--
Mr. Bryan Baum
Mr. Bryan Baum
Director
Director
--
--
Ms. Frances D. Schulz
Ms. Frances D. Schulz
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 24
Updated: Mon, Nov 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Celadon Partners SPV 24
37.19%
New Enterprise Associates (NEA)
14.36%
Bayer HealthCare LLC
10.69%
PharmaEssentia Corp.
8.03%
Nantahala Capital Management, LLC
3.38%
Other
26.36%
Shareholders
Shareholders
Proportion
Celadon Partners SPV 24
37.19%
New Enterprise Associates (NEA)
14.36%
Bayer HealthCare LLC
10.69%
PharmaEssentia Corp.
8.03%
Nantahala Capital Management, LLC
3.38%
Other
26.36%
Shareholder Types
Shareholders
Proportion
Corporation
55.90%
Venture Capital
14.46%
Hedge Fund
3.76%
Investment Advisor
3.39%
Individual Investor
0.85%
Investment Advisor/Hedge Fund
0.69%
Other
20.95%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
48
7.00M
26.75%
-1.06M
2025Q2
59
22.40M
85.87%
+17.02M
2025Q1
61
32.06M
123.04%
+28.81M
2024Q4
55
2.74M
57.01%
+442.53K
2024Q3
56
2.03M
44.31%
-591.63K
2024Q2
59
2.00M
43.68%
-736.88K
2024Q1
91
2.11M
47.03%
-1.57M
2023Q4
97
2.11M
47.62%
-1.61M
2023Q3
101
2.43M
55.03%
-1.49M
2023Q2
105
2.45M
55.45%
-1.56M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Celadon Partners SPV 24
9.78M
37.37%
--
--
Aug 29, 2025
New Enterprise Associates (NEA)
3.78M
14.43%
--
--
Jun 30, 2025
Bayer HealthCare LLC
2.81M
10.74%
+2.22M
+377.99%
Mar 10, 2025
PharmaEssentia Corp.
2.11M
8.07%
--
--
Apr 28, 2025
Nantahala Capital Management, LLC
888.00K
3.39%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
360.91K
1.38%
+206.78K
+134.15%
Jun 30, 2025
8VC GP I, LLC
253.75K
0.97%
--
--
Jun 30, 2025
Lu (Timothy K M.D., Ph.D.)
161.63K
0.62%
--
--
Apr 28, 2025
Geode Capital Management, L.L.C.
147.31K
0.56%
+117.59K
+395.57%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0%
ARK Genomic Revolution ETF
0%
iShares Micro-Cap ETF
Proportion0%
ARK Genomic Revolution ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Date
Type
Ratio
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
FAQs
Who are the top five shareholders of Senti Biosciences Inc?
The top five shareholders of Senti Biosciences Inc are:
Celadon Partners SPV 24 holds 9.78M shares, accounting for 37.37% of the total shares.
New Enterprise Associates (NEA) holds 3.78M shares, accounting for 14.43% of the total shares.
Bayer HealthCare LLC holds 2.81M shares, accounting for 10.74% of the total shares.
PharmaEssentia Corp. holds 2.11M shares, accounting for 8.07% of the total shares.
Nantahala Capital Management, LLC holds 888.00K shares, accounting for 3.39% of the total shares.
Celadon Partners SPV 24 holds 9.78M shares, accounting for 37.37% of the total shares.
New Enterprise Associates (NEA) holds 3.78M shares, accounting for 14.43% of the total shares.
Bayer HealthCare LLC holds 2.81M shares, accounting for 10.74% of the total shares.
PharmaEssentia Corp. holds 2.11M shares, accounting for 8.07% of the total shares.
Nantahala Capital Management, LLC holds 888.00K shares, accounting for 3.39% of the total shares.
What are the top three shareholder types of Senti Biosciences Inc?
The top three shareholder types of Senti Biosciences Inc are:
Celadon Partners SPV 24
New Enterprise Associates (NEA)
Bayer HealthCare LLC
Celadon Partners SPV 24
New Enterprise Associates (NEA)
Bayer HealthCare LLC
How many institutions hold shares of Senti Biosciences Inc (SNTI)?
As of 2025Q3, 48 institutions hold shares of Senti Biosciences Inc, with a combined market value of approximately 7.00M, accounting for 26.75% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -59.12%.
What is the biggest source of revenue for Senti Biosciences Inc?
In --, the -- business generated the highest revenue for Senti Biosciences Inc, amounting to -- and accounting for --% of total revenue.
